Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: 4,980 + web + 0.30  Related to the article below (Last Update: 8/4/2008)

Ness Technologies Announces Record Second Quarter 2008 Financial ...
IT News Online, India - Jul 29, 2008
0.13 $ 0.25 $ 0.30 $ 0.47 Weighted average number of shares (in thousands) used in computing non-GAAP diluted net earnings per share. ...NSTC
Source: Google News

Web Impact Factors for Iranian Universities -
A Noruzi - Webology, 2005 - webology.ir
... Impact Factor, F Inlinks coming from domains except IR (Iran), G English pages in
the web site, H ... University of Kashan, 0.70, 3490, 1470, 1290, 4980, 0.30, 506, ...

[PDF] … Accumulation of Polychlorinated Biphenyl Congeners in the Terrestrial Food Web of the Kalamazoo … -
AL Blankenship, MJ Zwiernik, KK Coady, DP Kay, JL … - Environmental Science & Technology, 2005 - msu.edu
... American robin adults 17 4.3 0.92 ( 1.2 e 0.30 4 2.3 0.091 ( 0.15 0.030 ... and Mammalian
TEQs among Various Trophic Levels in the Terrestrial Food Web at Both the ...

BODY WATER COMPOSITION IN KWASHIORKOR BEFORE AND AFTER
LOF EDEMA - Pediatrics, 1965 - Am Acad Pediatrics
... http://www.pediatrics.org the World Wide Web at: The online version of this article,
along with updated information and services ... 4980 5290 4930 4420 5260 4920 ...

[PDF] Development of Design Criteria for RC Interior Beam-Column Joints -
K Kitayama, S Otani, H Aoyama - Design of Beam-Column Joints for Seismic Resistance, 1991 - sake.arch.tu-tokyo.ac.jp
... transverse beams failed in diagonal compression of the joint core concrete, develop
ping the joint shear strength of 0.30 ' ... f y (kgf/cm 2 ) 3750 3300 4980 4980 ...

Short Communication: User friendly and ?useworthy?Stress Barometer -
G Brattberg, LTH Certec - Stress and Health, 2006 - doi.wiley.com
... 0.72) Can?t just ?do nothing? 0.51 (0.30?0.68) Have a ... Lakartidningen, 99(49),
4974?4980. ... Retrieved October 17, 2005, from Certec Web site: http://www ...

[PDF] KDD for Personalization
B Mobasher, B Berendt, M Spiliopoulou - Tutorial 5th European Conf. Principles and Practice of … - maya.cs.depaul.edu
... more Web servers ... 203.252.234.33 www.acr-news.org - [01/Jun/1999:03:32:31 -0600]
"GET / HTTP/1.0" 200 4980 "" "Mozilla/4.06 [en] (Win95; I)" ...

Effects of converting enzyme inhibition on heart period variability in patients with acute … -
D Bonaduce, F Marciano, M Petretta, ML Migaux, G … - Circulation, 1994 - Am Heart Assoc
... http://circ.ahajournals.org located on the World Wide Web at: The online ... 8.47?0.30
(P<.01); considering the frequency bands, a signif- icant increase was ...

[PDF] Learning hard constraints in Max-SAT
J Argelich, F Manya - In 11th Annual ERCIM Workshop on Constrant Solving and …, 2006 - udl.es
... 3col80 5 6 76 47522 0.63 1.60 >24h 11 3col80 5 7 80 26159 0.30 0.89 >24h 3.23 ... ezfact32
3 397 529 4886 9652 >24h 128 ezfact32 4 379 260 2627 4980 >24h 828 ...

[PDF] Lawrence Berkeley National Laboratory -
ACPP Field - repositories.cdlib.org
... facility. The technology used for the communications is known as Extensible
Markup Language (XML) with ?Web services?. Control ...

Organic photovoltaic cells with high open circuit voltages based on pentacene derivatives
LC Palilis, PA Lane, GP Kushto, B Purushothaman, … - Organic Electronics, 2008 - Elsevier
... (For interpretation of the references to colour in this figure legend, the reader
is referred to the web version of this article.). ... (0.30 V) [5] and Yoo et al. ...

Source: Google Scholar
 
 

FDA approves Avelox for treatment of complicated skin and skin structure infections

 
 
FDA ( Food and Drug Administration ) approved the once-daily antibiotic Moxifloxacin ( Avelox ) for the treatment of complicated skin and skin structure infections ( cSSSI ) in adults caused by Methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae or Enterobacter cloacae.

There are 2.5 million cSSSI cases in the U.S. annually, with approximately 400,000 patients requiring hospitalization.
Treatment of these infections typically involve high doses of antibiotics, often requiring multiple doses per day.

" Complicated skin and skin structure infections can be severe and may require surgery to resolve," said Ellie J.C. Goldstein, director of the R.M. Alden Research Laboratory, Santa Monica, and at David Geffen School of Medicine at UCLA, Los Angeles. "Since Avelox features once-a-day administration, it offers a convenient and effective treatment option for patients," he said.

In the studies on which the FDA approval was based, sequential intravenous or oral monotherapy with Avelox once daily for cSSSI patients demonstrated similar efficacy to IV Piperacillin-Tazobactam four times daily followed by oral amoxicillin-clavulanate twice daily.

The FDA approval to treat cSSSI is the fifth indication for Avelox, which is currently approved in the United States to treat acute bacterial sinusitis ( ABS ), acute bacterial exacerbation of chronic bronchitis ( ABECB ), community acquired pneumonia ( CAP ) and uncomplicated skin and skin structure infections ( uSSSI ).

Two randomized, active controlled trials in cSSSI were performed. A double-blind, prospective, multicenter trial was conducted primarily in North America to compare the efficacy of sequential intravenous ( IV ) or oral ( PO ) monotherapy with Avelox 400 mg once daily ( QD ) for 7-14 days to an IV/PO beta-lactam/beta-lactamase inhibitor control in the treatment of patients with cSSSI.

This study enrolled 617 patients, of which 335 were valid for the primary efficacy analysis. Infections observed in both patient groups included abscess, cellulitis, ischemic/decubitus ulcer, surgical wound infection and traumatic lesion.

A second open-label international study compared Avelox 400 mg QD for 7-21 days to sequential IV/PO beta-lactam/beta- lactamase inhibitor control in the treatment of patients with cSSSI. This study enrolled 804 patients, 632 of which were valid for primary efficacy analysis.

In the North American trial, the overall success rates in evaluable patients for Avelox versus the comparator were 77.2 percent and 81.5 percent, respectively.
In this study, Avelox demonstrated similar efficacy to the comparator, 82.2 percent and 87.6 percent, respectively, in eradicating methicillin-susceptible strains of Staphylococcus aureus, one of the key pathogens that cause cSSSI.
Pooled clinical success rates by pathogen in the North American and international trials for Avelox versus the comparator, respectively, were 81.6 percent and 84.8 percent for E. coli; 91.7 percent and 70 percent for K. pneumoniae; and 81.8 percent versus 57.1 percent for E. cloacae.

Broad categories of skin and skin structure infections ( e.g., superficial skin infections, cellulitis and simple abscesses ) tend to share common bacterial causes.
Skin and skin structure infections that are diagnosed as complicated involve deeper soft tissue ( e.g., muscle, fat ), may require significant surgical intervention to resolve ( e.g., infected ulcers, burns, major abscesses ) or are associated with an underlying disease state that complicates response to treatment. The possible bacterial causes of cSSSI are numerous and depend on the clinical situation, the location of the lesion or infection, and past medical history of the individual patient.

Avelox is approved to treat:

- acute bacterial exacerbations of chronic bronchitis ( ABECB ) caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Staphylococcus aureus, or Moraxella catarrhalis; Acute Bacterial Sinusitis (ABS) caused by Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis;

- community acquired pneumonia (CAP) caused by Streptococcus pneumoniae ( including multi- drug resistant strains ), Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydia pneumoniae;

- uncomplicated skin and skin structure infections ( uSSSI ) caused by Staphylococcus aureus or Streptococcus pyogenes; and Complicated Skin and Skin Structure Infections ( cSSSI ) caused by Methicillin susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae.

Avelox is generally well tolerated, with adverse events being similar to standard therapy. The most common side effects caused by Avelox, which are usually mild, include dizziness, nausea and diarrhea. Patients should be careful about driving or operating machinery until they are sure that Avelox is not causing dizziness. Patients should inform a health care professional of other side effects.

Patients who have ever had an allergic reaction to Avelox or any of the other group of antibiotics known as " quinolones," such as Ciprofloxacin or Levofloxacin should avoid taking Avelox.

Patients who have been diagnosed with an abnormal heartbeat such as an arrhythmia or are using certain medications used to treat an abnormal heartbeat should avoid taking Avelox. These medications include Quinidine, Procainamide, Amiodarone, and Sotalol.

Avelox is not for use during pregnancy or nursing, as the effects on the unborn child or nursing infant are unknown. Avelox is not for children under the age of 18 years.

Convulsions have been reported in patients receiving Quinolone antibiotics. Patients should be sure to let their physician know if they have a history of convulsions.

Many antacids and multivitamins may interfere with the absorption of Avelox and may prevent it from working properly. Patients should take Avelox either 4 hours before or 8 hours after taking these products.

Source: Schering-Plough, 2005
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; Nedws9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page